Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies
Numinus Wellness Provides Update Regarding Listing Status
Numinus Wellness Provides Corporate Update
Numinus Wellness Advises of a Change of Auditor
Numinus Wellness Inc. (OTCMKTS:NUMIF) Short Interest Update
Numinus Wellness Provides Corporate Update
Numinus Wellness Announces Change of Auditor
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results
Numinus Wellness Inc. Announces First Quarter Fiscal 2025 Results
Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2024 Results
Numinus Approved as a State-Certified Natural Medicine Training Program in Colorado
Numinus Wellness Inc. Announces CFO Transition
Numinus Wellness Inc. Announces Strategic Wind-Down of Non-Operating Subsidiaries
Numinus Wellness Announces Corporate Update
Numinus Provides Bi-Weekly Update on Annual Filings
Numinus Provides Bi-Weekly Update on Annual Filings
Numinus Wellness Closes Sale of Clinics and Launches Initiative to Increase Access to Mental Health Care
Numinus Provides Bi-Weekly Update on Annual Filings
Numinus Applies for Management Cease Trade Order
Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care
Numinus Wellness Comments on FDA Decision on New Drug Application for MDMA-Assisted Therapy for PTSD
Numinus Wellness Inc. (NUMIF) Q3 2024 Earnings Call Transcript
Numinus Wellness Inc. Announces Third Quarter Fiscal 2024 Results
Numinus to Host Q3 Fiscal 2024 Results Conference Call on July 11, 2024
Numinus Wellness Announces Resignation of Director
Numinus Wellness Announces Strategic Acquisition of MedBright AI
MedBright AI Announces Strategic Acquisition by Numinus Wellness
Numinus Clarifies Disclosures
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD
Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders
Numinus Wellness Charts Path To Profitability While Strengthening Community Ties
Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003
Numinus Wellness Inc. (NUMIF) Q2 2024 Earnings Call Transcript
Numinus Wellness Provides Corporate Update
Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results
Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024
Numinus Wellness Submits Clinical Trial Application
Numinus Wellness Provides Corporate Update
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C.
/C O R R E C T I O N from Source -- Numinus Wellness Inc./
Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.
Numinus Wellness Inc. (NUMIF) Q1 2024 Earnings Call Transcript
Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results
Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024
Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study